<DOC>
	<DOC>NCT00986284</DOC>
	<brief_summary>This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in stage IIIA NSCLC patients.</brief_summary>
	<brief_title>Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Patients pathological diagnosed with NSCLC,with EGFR sensitive mutation; Stage IIIA patients with technical operable disease evaluated by image and lab results; Patients without chemotherapy or targetedtherapy before; Inform Consent. Patients with malignant tumor other than lung cancer; Patients with other diseases such as cardiovascular disease that may hamper follow up; Patients that may not coordinate well,judged by researcher.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>Neoadjuvant Therapy</keyword>
</DOC>